Tygacil Hospital Antibiotic Launch Expected Within 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth hopes to launch the injectable antibiotic Tygacil (tigecycline) within the next 12 months, CEO Robert Essner told the Bear Stearns conference in New York Sept. 14.
You may also be interested in...
Wyeth Touts Tygacil As First Global NDA Submission
The first-in-class glycylcycline antibiotic could be a monotherapy option in the treatment of complicated infections, Wyeth says. The company would likely detail the injectable alongside its antibiotic Zosyn.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.